Radionuclide Drug Conjugates (RDC) Market by Type -
Radionuclide Drug Conjugates (RDC) Market by Disease Indication -
Radionuclide Drug Conjugates (RDC) Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radionuclide Drug Conjugates (RDC) Market Snapshot
Chapter 4. Global Radionuclide Drug Conjugates (RDC) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Pipeline Analysis
4.7. Industry Analysis – Porter’s Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. By Type, & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the
5.2.1. Antibody Radionuclide Conjugates (ARC)
5.2.2. Peptide Radionuclide Conjugates (PRC)
5.2.3. Small Molecular Radionuclide Conjugates (SMRC)
Chapter 6. Market Segmentation 2: By Disease Indication Estimates & Trend Analysis
6.1. By Disease Indication & Market Share, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the
6.2.1. Neuroendocrine Tumors
6.2.2. Prostate Cancer
6.2.3. Renal Cell Carcinoma
6.2.4. Others
Chapter 7. Radionuclide Drug Conjugates (RDC) Market Segmentation 5: Regional Estimates &
Trend Analysis
7.1. North America
7.1.1. North America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million)
estimates and forecasts By Type, 2019-2031
7.1.2. North America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million)
estimates and forecasts By Disease Indication, 2019-2031
7.1.3. North America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million)
estimates and forecasts by Country, 2019-2031
7.2. Europe
7.2.1. Europe Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By Type,
2019-2031
7.2.2. Europe Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Disease Indication, 2019-2031
7.2.3. Europe Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) by
Country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Type, 2019-2031
7.3.2. Asia Pacific Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Disease Indication, 2019-2031
7.3.3. Asia Pacific Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) by
Country, 2019-2031
7.4. Latin America
7.4.1. Latin America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Type, (US$ Million) 2019-2031
7.4.2. Latin America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Disease Indication, (US$ Million) 2019-2031
7.4.3. Latin America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) by
Country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market revenue (US$
Million) By Type, (US$ Million) 2019-2031
7.5.2. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market revenue (US$)
Million) By Disease Indication, (US$ Million) 2019-2031
7.5.3. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market revenue (US$
Million) by Country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Telix Pharmaceuticals Limited
8.2.2. Grand Pharma
8.2.3. Bayer AG
8.2.4. Novartis AG
8.2.5. Lantheus
8.2.6. Curium Pharma
8.2.7. Yantai Lannacheng Biotechnology Co., Ltd
8.2.8. BoomRay Pharmaceuticals
8.2.9. Hengrui Medicine
8.2.10. Yunnan Baiyao Group
8.2.11. Sinotau
8.2.12. SmartNuclide Biopharma
8.2.13. Yuanda Pharmaceutical
8.2.14. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.